Tenon Medical Q1 Revenue Rises 90% to $1.4M; Closes $4.3M Financing
Tenon Medical reported Q1 2026 revenue of $1.4M, up 90% year-over-year, and gross profit of $0.9M, up 193%, with gross margin expanding to 68.5%. The company closed a $4.3M senior convertible note placement and opened a new training center in Tampa to support commercial expansion.
1. Q1 Financial Performance
Tenon Medical generated $1.4 million in revenue for the quarter ended March 31, 2026, a 90% increase from $0.7 million in Q1 2025, driven by higher adoption of its Catamaran® and SImmetry®+ SI joint fusion systems. Gross profit surged 193% to $0.9 million and gross margin expanded 24 percentage points to 68.5% due to greater production overhead absorption.
2. Financing and Cash Position
The company closed a senior convertible note private placement for gross proceeds of $4.3 million, bolstering its cash position to $4.6 million as of quarter end, up from $3.8 million at year-end 2025. Net loss narrowed slightly to $3.5 million, or $0.31 per share, from $3.6 million, or $1.01 per share, a year earlier.
3. Patent Portfolio Expansion
During Q1, Tenon Medical secured multiple Notices of Allowance from the U.S. Patent and Trademark Office, building on 29 issued U.S. patents and nine international patents, with 31 pending applications. These developments reinforce intellectual property protection around its Catamaran® and SImmetry®+ systems ahead of expected issuances in 2026.
4. Commercial Expansion and Training
Subsequent to quarter end, the company opened a Center of Excellence training facility in Tampa, Florida, and expanded its sales leadership across the Eastern region. It hosted 21 physicians in targeted sessions, aiming to accelerate procedure volume growth and deepen surgeon engagement with its multi-approach SI joint fusion portfolio.